ID | 118849 |
タイトル別表記 | AMD-associated submacular hemorrhage
|
著者 |
Inoue, Naomi
Nagoya City University|J-CREST (Japanese Clinical Retina Study) Group
Kato, Aki
Nagoya City University|J-CREST (Japanese Clinical Retina Study) Group
Araki, Takashi
J-CREST (Japanese Clinical Retina Study) Group|Hyogo College of Medicine
Kimura, Takeshi
J-CREST (Japanese Clinical Retina Study) Group|Hyogo College of Medicine
木下, 貴正
J-CREST (Japanese Clinical Retina Study) Group)|Sapporo City General Hospital
Okamoto, Fumiki
J-CREST (Japanese Clinical Retina Study) Group|University of Tsukuba
Murakami, Tomoya
J-CREST (Japanese Clinical Retina Study) Group|University of Tsukuba
三田村, 佳典
J-CREST (Japanese Clinical Retina Study) Group|Tokushima University
徳島大学 教育研究者総覧
KAKEN研究者をさがす
Sakamoto, Taiji
J-CREST (Japanese Clinical Retina Study) Group|Kagoshima University
Miki, Akiko
J-CREST (Japanese Clinical Retina Study) Group|Kobe University
Takamura, Yoshihiro
J-CREST (Japanese Clinical Retina Study) Group|University of Fukui
Matsubara, Hisashi
J-CREST (Japanese Clinical Retina Study) Group|Mie University
Tsujinaka, Hiroki
J-CREST (Japanese Clinical Retina Study) Group|Nara Medical University
Gomi, Fumi
J-CREST (Japanese Clinical Retina Study) Group|Hyogo College of Medicine
Yasukawa, Tsutomu
Nagoya City University|J-CREST (Japanese Clinical Retina Study) Group
|
資料タイプ |
学術雑誌論文
|
抄録 | Purpose
To investigate the clinical features, treatment options, and visual outcomes of submacular hemorrhage (SMH) secondary to neovascular age-related macular degeneration (nAMD). Design A retrospective, observational case series. Methods Setting: Multicenter institutional setting. Patient Population: A total of 127 patients (127 eyes; 88 men, 39 women; (mean age, 74.2 years)) diagnosed with AMD-associated SMHs exceeding 2 disc diameters involving the fovea. Observation: The AMD types, previous treatments, treatment options, anatomic findings, and best-corrected visual acuity (BCVA) were assessed. Main Outcome Measures: Clinical features, treatment options, and visual outcomes of SMHs secondary to nAMD. Results Thirty-two eyes had typical AMD, 94 eyes polypoidal choroidal vasculopathy (PCV), and one eye retinal angiomatous proliferation. Eighty-five eyes were treatment-naïve; 42 eyes were treated previously: anti-vascular endothelial growth factor (VEGF) therapy (n = 26), photodynamic therapy (n = 3), and combined therapy (n = 13). Treatment of SMHs included vitrectomy (36 eyes), pneumatic displacement (49 eyes), and anti-VEGF monotherapy (42 eyes). The final BCVA improved significantly in treatment-naïve cases from 0.86 to 0.62 logarithm of the minimal angle of resolution (logMAR) unit (Snellen equivalent from 20/145 to 20/83) and from 0.80 to 0.56 (Snellen equivalent from 20/126 to 20/73) in PCV cases. Meanwhile, the BCVA logMAR values improved from 1.15 to 0.75 (Snellen equivalent from 20/283 to 20/112) and from 0.87 to 0.63 (Snellen equivalent from 20/148 to 20/85) in eyes that underwent vitrectomy or pneumatic displacement, respectively. In eyes with BCVAs between 20/133 to 20/40 at SMH onset, the final VA in the pneumatic displacement group was better than in the anti-VEGF monotherapy group. One eye had a retinal detachment and 1 eye had a macular hole in the vitrectomy group, and 5 eyes had a vitreous hemorrhage in the pneumatic displacement group. Conclusions The recommended treatment for SMHs secondary to nAMD exceeding 2 disc area and with BCVA below 20/40 is vitrectomy or pneumatic displacement for visual improvement. |
掲載誌名 |
PLOS ONE
|
ISSN | 19326203
|
出版者 | PLOS
|
巻 | 17
|
号 | 7
|
開始ページ | e0271447
|
発行日 | 2022-07-21
|
権利情報 | This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
EDB ID | |
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
出版社版
|
部局 |
病院
医学系
|